HLA DRB1 Alleles and Hepatitis C Virus Infection in Chronic Kidney Disease Patients

Shaheen, N.; Soliman, Amin R.; El-Khashab, Sahier Omar; Hanna, Mark P.

doi:10.3109/0886022x.2012.761038

Cited by 7 publications

(4 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies have demonstrated a heterozygote advantage for classical HLA class II genes in the context of human HBV infection ( 43 ), HBV-associated hepatocellular carcinoma ( 45 ), and in patients with ulcerative colitis ( 44 ). Moreover, a heterozygote advantage has also been reported by Hraber et al ( 46 ) in the context of HCV infection but this could not be confirmed in an independent study by Shaheen et al ( 47 ). A heterozygote advantage in classical HLA class I loci has been documented in the context of HIV infection, as this virus produces escape variants during chronic infection at a considerable frequency ( 1 ).…”

Section: Discussionmentioning

confidence: 81%

Human leukocyte antigen class II gene diversity tunes antibody repertoires to common pathogens

et al. 2022

View full text Add to dashboard Cite

Allelic diversity of human leukocyte antigen (HLA) class II genes may help maintain humoral immunity against infectious diseases. In this study, we investigated germline genetic variation in classical HLA class II genes and employed a systematic, unbiased approach to explore the relative contribution of this genetic variation in the antibody repertoire to various common pathogens. We leveraged a well-defined cohort of 800 adults representing the general Arab population in which genetic material is shared because of the high frequency of consanguineous unions. By applying a high-throughput method for large-scale antibody profiling to this well-defined cohort, we were able to dissect the overall effect of zygosity for classical HLA class II genes, as well as the effects associated with specific HLA class II alleles, haplotypes and genotypes, on the antimicrobial antibody repertoire breadth and antibody specificity with unprecedented resolution. Our population genetic studies revealed that zygosity of the classical HLA class II genes is a strong predictor of antibody responses to common human pathogens, suggesting that classical HLA class II gene heterozygosity confers a selective advantage. Moreover, we demonstrated that multiple HLA class II alleles can have additive effects on the antibody repertoire to common pathogens. We also identified associations of HLA-DRB1 genotypes with specific antigens. Our findings suggest that HLA class II gene polymorphisms confer specific humoral immunity against common pathogens, which may have contributed to the genetic diversity of HLA class II loci during hominine evolution.

show abstract

Section: Discussionmentioning

confidence: 81%

Human leukocyte antigen class II gene diversity tunes antibody repertoires to common pathogens

et al. 2022

View full text Add to dashboard Cite

show abstract

“…For the meta-analysis aimed to determine the association of HLA DRB*12 with ESRD, eighteen studies were selected ( Ademović-Sazdanić & Vojvodić, 2019 ; Almogren, Shakoor & Hamam, 2012 ; Bhallil et al, 2017 ; Chowdhry, Makroo & Kumar, 2016 ; Dai et al, 2015a ; Hamdi, Al-Hababi & Eid, 2014 ; Hieu, Ha & Nghi, 2019 ; Karahan et al, 2009 ; Kodaz, Akdeniz & Cengiz, 2017 ; Mosaad et al, 2014 ; Nassar et al, 2017 ; Nassar, Al-Shamahy & Masood, 2015 ; Pan et al, 2019 ; Patel et al, 2013 ; Pérez-Luque et al, 2000 ; Shaheen et al, 2013 ; Shang et al, 2016 ). These analyses showed a cumulative OR of 1.05, 95% CI [0.94, 1.18] in a random effect model for ESRD patients compared with healthy individuals ( Fig.…”

Section: Resultsmentioning

confidence: 99%

“…Significant heterogeneity was found among the studies (Chi 2 = 28.01, P = 0.04, I 2 = 39%). Seven studies showed a positive association between HLA DRB*13 and ESRD ( Chowdhry, Makroo & Kumar, 2016 ; Hamdi, Al-Hababi & Eid, 2014 ; Mosaad et al, 2014 ; Nassar et al, 2017 ; Nassar, Al-Shamahy & Masood, 2015 ; Pérez-Luque et al, 2000 ; Shaheen et al, 2013 ). However, there was no statistically significant negative association between ESRD and DRB*13 (OR = 0.90, CI [0.81, 1.01]) ( P = 0.07) ( Fig.…”

Section: Resultsmentioning

confidence: 99%

Association between human leukocyte antigen (HLA) and end-stage renal disease (ESRD): a meta-analysis

Noureen

Zaidi

2023

PeerJ

View full text Add to dashboard Cite

Objectives We recently studied the association between various human leukocyte antigen (HLA) alleles and end-stage renal disease (ESRD). According to our analysis, HLA-B*50 and HLA-DQA1*3 alleles were positively associated with ESRD, while B*40, DRB1*12, DRB1*13, and DQA1*6 alleles were negatively associated with ESRD. However, a single case-control study does not have enough statistical power to evaluate the possible impact of genetic polymorphism on any disease. Hence, the main objective of this meta-analysis is to determine the association between these abovementioned HLA alleles and ESRD. Design MEDLINE/PubMed, EMBASE, Web of Science, and Cochrane databases were searched through December 2020 for case-control studies on the associations between HLA polymorphisms and ESRD. Independent reviewers screened the texts of potentially eligible studies and assessed the risk of bias. The meta-analysis was conducted based on the checklists and guidelines based on PRISMA. Results We identified 26 case-control studies comprising 1,312 ESRD and 3,842 healthy subjects. A non-significant positive association was observed between HLA-B*50 (OR = 1.02, 95% CI [0.90, 1.24]), HLA-B*40 (OR = 1.75, 95% CI [0.98, 3.2]), HLA-DQA1*3, (OR = 1.17, 95% CI [0.74, 1.84]), DRB1*12 (OR = 1.05, 95% CI [0.94, 1.18]) alleles and ESRD. In addition, a non-significant negative association was observed between HLA-DRB1*13 (OR = 0.90, CI [0.81, 1.01]), HLA-DQB1*6 (OR = 0.79, 95% CI [0.58, 1.07]) alleles and ESRD. Conclusions Our meta-analysis indicates no significant association between HLA-B*50, HLA-DQA1*3, B*40, DRB1*12, DRB1*13, and DQA1*6 alleles and ESRD. Further studies with larger sample sizes and adjustments for confounders are required to confirm these conclusions.

show abstract

“…To our knowledge, HLA-associated alleles in Egyptian patients with hepatitis C have been studied using current methods include Sequence-Specific Oligonucleotide Probe Hybridization (SSOPH), Sequence-Specific Primers (SSP) and PCR-SSO luminex technology which are costly and require multiple steps (Shaker et al, 2013;Shaheen et al, 2013;Yosry et al, 2011).…”

Section: Introductionmentioning

confidence: 99%

The Association of HLA Class II Alleles with the Response to Alfa-Interferon/Ribavirin Therapy in Chronic Hepatitis C Patients

Gawish¹,

Mohammed²,

Hussein³

et al. 2015

American Journal of Immunology

View full text Add to dashboard Cite

Human Leucocyte Antigens (HLA) class II appears to play an important role in the individual's immune response to viral infection. The present study was aimed at assessment of the relationship between HLA DRB1 alleles and the response to HCV combined therapy in Chronic Hepatitis C patients (CHC). We enrolled a total of 44 chronically infected HCV patients without Hepatitis B Virus (HBV) or Human Immunodeficiency Virus (HIV). Their mean age was 36.45±11.18 years (21-63). HLA-DRB1 typing was done by real time Polymerase Chain Reaction (PCR). ALT and Hemoglobin (Hb) levels were assessed as well as viral genotype was taken from patients' reports (HCV genotypes were 1, 2, 3 and 4 representing 13.6, 13.6, 4.5 and 68.18%, respectively). The most frequent alleles demonstrated among patients were DRB1*13 and DRB1*07 (31.8 and 36.4%, respectively). Analysis of DRB1 frequency between sustained responders and non responders revealed that DRB1*13 allele was significantly higher among sustained responders (p<0.001), while DRB1*07 allele was significantly higher among non responders (p<0.01). Female sex, HCV genotype 2 and pretreatment low serum HCV RNA level were associated with Sustained Virological Response (SVR). Also, elevated Alanine aminotransferase (ALT) level at the 1st week of therapy followed by return to baseline level at the 4th week and a decrease of the mean hemoglobin concentration at 4th week and 12th week of therapy were significantly associated with SVR. We concluded that the virological and special HLA patterns may possibly predict the response to combination therapy in CHC patients.

show abstract

HLA DRB1 Alleles and Hepatitis C Virus Infection in Chronic Kidney Disease Patients

Cited by 7 publications

References 27 publications

Human leukocyte antigen class II gene diversity tunes antibody repertoires to common pathogens

Human leukocyte antigen class II gene diversity tunes antibody repertoires to common pathogens

Association between human leukocyte antigen (HLA) and end-stage renal disease (ESRD): a meta-analysis

The Association of HLA Class II Alleles with the Response to Alfa-Interferon/Ribavirin Therapy in Chronic Hepatitis C Patients

Contact Info

Product

Resources

About